GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer

被引:0
作者
Tatenuma, Tomoyuki [1 ,2 ]
Matsukawa, Takuo [1 ,2 ]
Goto, Takuro [1 ,2 ]
Jiang, Guiyang [1 ,2 ]
Sharma, Adhya [1 ,2 ]
Najafi, Mohammad amin elahi [1 ,2 ]
Teramoto, Yuki [1 ,2 ]
Miyamoto, Hiroshi [1 ,2 ,3 ,4 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Avenue,Box 626, Rochester, NY 14642 USA
[2] Univ Rochester, James P Wilmot Canc Inst, Med Ctr, Rochester, NY USA
[3] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY USA
[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA
关键词
Bladder cancer; chemotherapy; cisplatin; estrogen receptor-beta; GULP1; ANDROGEN RECEPTOR; EXPRESSION;
D O I
10.21873/cgp.20472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Precise molecular mechanisms underlying resistance to cisplatin-based chemotherapy remain unclear, while the activity of estrogen receptor-/3 (ER/3) has been suggested to be associated with chemosensitivity in urothelial cancer. We aimed to determine if GULP1, an adapter protein known to facilitate phagocytosis, could represent a downstream effector of ER/3 and thereby modulate cisplatin sensitivity in bladder cancer. Materials and Methods: GULP1 expression and cisplatin cytotoxicity were compared in bladder cancer lines. Immunohistochemistry was used to determine the expression of GULP1 and ER/3 in two sets of tissue microarray (TMA) consisting of transurethral resection specimens. Results: The levels of GULP1 expression were considerably higher in ER/3- knockdown sublines than in the respective control ER/3-positive sublines. Estradiol treatment reduced GULP1 expression in ERa-negative/ER/3-positive lines, which was restored by the anti- estrogen tamoxifen. Chromatin immunoprecipitation assay revealed the binding of ER/3 to the GULP1 promoter in bladder cancer cells. Moreover, GULP1 knockdown sublines were significantly more resistant to cisplatin treatment, but not to other chemotherapeutic agents, including gemcitabine, methotrexate, vinblastine, and doxorubicin. In the first set of TMA (n=129), the expression of ER/3 and GULP1 was inversely correlated (p=0.023), and ER/3(-)/GULP1(+) in 51 muscle- invasive tumors was associated with significantly lower risk of disease progression and cancer-specific mortality. Similarly, in the second set (n=43), patients with ER/3(-)/GULP1(+) muscle- invasive disease were significantly (p=0.021) more likely to be responders to cisplatin-based neoadjuvant chemotherapy before radical cystectomy. Conclusion: ER/3 activation was found to reduce the expression of GULP1 as a direct downstream target in bladder cancer cells, resulting in the induction of cisplatin resistance.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 50 条
  • [41] Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism
    Matsunaga, Toshiyuki
    Suzuki, Ayaka
    Kezuka, Chihiro
    Okumura, Naoko
    Iguchi, Kazuhiro
    Inoue, Ikuo
    Soda, Midori
    Endo, Satoshi
    El-Kabbani, Ossama
    Hara, Akira
    Ikari, Akira
    CHEMICO-BIOLOGICAL INTERACTIONS, 2016, 256 : 142 - 153
  • [42] SRSF1-mediated alternative splicing regulates bladder cancer progression and cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis
    Qikai Wu
    Hao Yu
    Huanyou Sun
    Jiancheng Lv
    Juntao Zhuang
    Lingkai Cai
    Lingjing Jiang
    Yuhan Chen
    Yiran Tao
    Kexin Bai
    Haiwei Yang
    Xiao Yang
    Qiang Lu
    Journal of Translational Medicine, 23 (1)
  • [43] Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus
    Stossi, F.
    Madak-Erdogan, Z.
    Katzenellenbogen, B. S.
    ONCOGENE, 2012, 31 (14) : 1825 - 1834
  • [44] Knockdown of ZBTB11 impedes R-loop elimination and increases the sensitivity to cisplatin by inhibiting DDX1 transcription in bladder cancer
    Chen, Lei
    Liu, Zefu
    Tang, Huancheng
    Zhou, Zhaohui
    Chen, Jiawei
    Ma, Zikun
    Deng, Minhua
    Li, Xiangdong
    Wu, Yuanzhong
    Zheng, Lisi
    Zhou, Liwen
    Zheng, Xianchong
    Liu, Zhuowei
    CELL PROLIFERATION, 2022, 55 (12)
  • [45] Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer
    Sikder, Rahmat K.
    Ellithi, Moataz
    Uzzo, Robert N.
    Weader, David J.
    Metz, Alexander L.
    Behbahani, Ali
    McKenzie, Erica R.
    El-Deiry, Wafik S.
    Abbosh, Philip H.
    MOLECULAR CANCER RESEARCH, 2021, 19 (03) : 403 - 413
  • [46] Transcription factor PRRX1-activated ANXA6 facilitates EGFR-PKCα complex formation and enhances cisplatin sensitivity in bladder cancer
    Cao, Jinlong
    Chen, Siyu
    Wang, Jirong
    Fan, Xinpeng
    Liu, Shanhui
    Li, Xiaoran
    Yang, Li
    LIFE SCIENCES, 2024, 359
  • [47] Protein-Tyrosine Phosphatase H1 Increases Breast Cancer Sensitivity to Antiestrogens by Dephosphorylating Estrogen Receptor at Tyr537
    Suresh, Padmanaban S.
    Ma, Shao
    Migliaccio, Antimo
    Chen, Guan
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (01) : 230 - 238
  • [48] Antiestrogens Suppress Effects of Transforming Growth Factor-β in Breast Cancer Cells via the Signaling Axis Estrogen Receptor-α and Y-box Binding Protein-1
    Popp, Simone L.
    Joffroy, Christian
    Stope, Matthias B.
    Buck, Miriam B.
    Fritz, Peter
    Knabbe, Cornelius
    ANTICANCER RESEARCH, 2013, 33 (06) : 2473 - 2480
  • [49] MicroRNA-146b-5p/FDFT1 mediates cisplatin sensitivity in bladder cancer by redirecting cholesterol biosynthesis to the non-sterol branch
    Azhar, Nurul Amniyyah
    Paramanantham, Yogaambikai
    Nor, W. M. Farhan Syafiq B. W. M.
    Said, Nur Akmarina B. M.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2024, 176
  • [50] Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer
    Vickman, Renee E.
    Yang, Jiang
    Lanman, Nadia A.
    Cresswell, Gregory M.
    Zheng, Faye
    Zhang, Chi
    Doerge, R. W.
    Crist, Scott A.
    Mesecar, Andrew D.
    Hu, Chang-Deng
    Ratliff, Timothy L.
    MOLECULAR CANCER RESEARCH, 2019, 17 (06) : 1253 - 1263